

## TABLE OF CONTENTS

INTERMITTENT CLAUDICATION THERAPIES—EUROPE .....	6
Efficacy of Pharmaceutical Therapies .....	6
Difficult to Assess.....	6
Most Agents Not Consistently Effective .....	6
Ticlopidine and Gingko Biloba Special Extract .....	6
Statins and ACE Inhibitors .....	6
PLETAL.....	7
The Only IC Drug Therapy with Documented Efficacy.....	7
European Market History.....	7
PLETAL REVENUES.....	8
Data Source.....	8
Revenues—United Kingdom and Germany .....	8
PLETAL PRICE .....	9
U.K. Annual Cost of Pletal Therapy 2002-2007.....	9
U.K. Average Price of Pletal and Other IC Therapies.....	9
MARKET FOR IC THERAPIES—2000-2007 .....	9
Data Source.....	9
Western Europe Region Revenues 2000-2007 .....	10
Examination of Revenues by ICD-10 Diagnosis Code for Intermittent Claudication..	10
Methods.....	10
Declining Revenues .....	12
COMPARISON OF IC REVENUES AND THE ESTIMATED NUMBER OF PEOPLE WITH PAD AND IC BY COUNTRY .....	13
WESTERN EUROPE REVENUES BY COUNTRY 2000-2007 YEAR TO DATE .....	14
Germany Intermittent Claudication Revenues.....	14
Italy Intermittent Claudication Revenues .....	15
France Intermittent Claudication Revenues.....	15
United Kingdom Intermittent Claudication Revenues.....	16
Spain Intermittent Claudication Revenues.....	16
Scandinavia Intermittent Claudication Revenues .....	17
The Netherlands Intermittent Claudication Revenues .....	17
Greece Intermittent Claudication Revenues .....	18
Portugal Intermittent Claudication Revenues .....	18
Belgium Intermittent Claudication Revenues.....	19
Austria Intermittent Claudication Revenues.....	19
Switzerland Intermittent Claudication Revenues.....	20
EUROPE—CLINICAL TRIAL DESIGN AND REGULATORY REQUIREMENTS ..	20
PAD PREVALENCE IN EUROPE—ESTIMATION METHODS .....	21
Diehm Method .....	21
Diabetes Method .....	21
Modified Edinburgh Artery Study Method.....	21
Diabetes in Europe.....	22
PAD Prevalence by Country.....	22
Europe—Region and Country Specific Population Projections .....	22

WESTERN EUROPE—MARKET OVERVIEW .....	23
Regional Prevalence of PAD .....	23
Regional Prevalence of Intermittent Claudication .....	23
Potential Market for Pharmaceutical Therapies to Treat Intermittent Claudication.....	23
Largest Western European Markets—Germany, Italy and France .....	23
Western European Markets Ranked by Size.....	24
POTENTIAL MARKET FOR IC PHARMACEUTICAL THERAPIES	
BY COUNTRY.....	24
Germany.....	25
Intermittent Claudication 25% .....	25
Intermittent Claudication 12% .....	25
Italy .....	26
Intermittent Claudication 25% .....	26
Intermittent Claudication 12% .....	26
France.....	27
Intermittent Claudication 25% .....	27
Intermittent Claudication 12% .....	27
United Kingdom.....	28
Intermittent Claudication 25% .....	28
Intermittent Claudication 12% .....	28
Spain .....	29
Intermittent Claudication 25% .....	29
Intermittent Claudication 12% .....	29
Scandinavia.....	30
Intermittent Claudication 25% .....	30
Intermittent Claudication 12% .....	30
The Netherlands.....	31
Intermittent Claudication 25% .....	31
Intermittent Claudication 12% .....	31
Greece .....	32
Intermittent Claudication 25% .....	32
Intermittent Claudication 12% .....	32
Portugal.....	33
Intermittent Claudication 25% .....	33
Intermittent Claudication 12% .....	33
Belgium.....	34
Intermittent Claudication 25% .....	34
Intermittent Claudication 12% .....	34
Austria.....	35
Intermittent Claudication 25% .....	35
Intermittent Claudication 12% .....	35
Switzerland .....	36
Intermittent Claudication 25% .....	36
Intermittent Claudication 12% .....	36
EASTERN EUROPE—MARKET OVERVIEW.....	37
Regional Prevalence of PAD and IC .....	37

Potential Market for Pharmaceutical Therapies to Treat Intermittent Claudication.....	37
Largest Eastern European Markets—Poland and Romania.....	37
<b>POTENTIAL MARKET FOR IC PHARMACEUTICAL THERAPIES</b>	
<b>BY COUNTRY.....</b>	<b>37</b>
Poland .....	38
Intermittent Claudication 25% .....	38
Intermittent Claudication 12% .....	38
Romania .....	39
Intermittent Claudication 25% .....	39
Intermittent Claudication 12% .....	39
<b>COMPARISON OF WESTERN EUROPE, EASTERN EUROPE AND THE UNITED STATES.....</b>	<b>40</b>
Overview of the Prevalence of PAD and IC in the Three Regions .....	40
<b>POTENTIAL MARKET FOR PHARMACEUTICAL THERAPIES—MIGHT BE CONSIDERABLY LARGER.....</b>	<b>41</b>
Pharmaceuticals to Treat Non-IC Walking Symptoms Could Expand the Market .....	41
More Effective Therapies Might Expand the Market for Intermittent Claudication Medications.....	41
<b>APPENDIX A.....</b>	<b>42</b>
Countries Included in Western Europe .....	42
<b>APPENDIX B.....</b>	<b>43</b>
Countries Included in Eastern Europe .....	43
<b>REFERENCES .....</b>	<b>44</b>
<b>INDEX OF TABLES.....</b>	<b>50</b>
<b>DISCLOSURE STATEMENT.....</b>	<b>54</b>
Stock Ownership.....	54
<b>CONTACT INFORMATION.....</b>	<b>55</b>